<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02174068</url>
  </required_header>
  <id_info>
    <org_study_id>CHU-0191</org_study_id>
    <secondary_id>2014-000624-22</secondary_id>
    <nct_id>NCT02174068</nct_id>
  </id_info>
  <brief_title>A Pharmacokinetic Drug Interaction and Tolerance Study of Paracetamol and Nefopam</brief_title>
  <acronym>PARA-NEF</acronym>
  <official_title>A Pharmacokinetic Drug Interaction and Tolerance Study of Paracetamol and Nefopam</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Clermont-Ferrand</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital, Clermont-Ferrand</source>
  <brief_summary>
    <textblock>
      Pain remains the leading cause of consultation. Despite a wide therapeutic arsenal, a
      significant percentage of patients disclaim little or no pain relief with common analgesics,
      specific or not their type of pain. This is especially true in cases of chronic pain, and
      current treatments are associated with many side effects. A need for therapeutic innovation
      is needed. Paracetamol is currently the most widely used analgesic worldwide but despite its
      excellent safety, its analgesic effect is limited from moderate to severe pain. Many
      analgesic drug combinations include paracetamol, recently the co-administration of
      paracetamol and nefopam showed a supra-additive antinociceptive effect (Van Elstraete AC et
      al. 2013). The development of a formulation associating paracetamol and nefopam first
      requires searching a possible pharmacokinetic interaction between the two active substances
      and assessing safety of this combination in healthy volunteers. No published studies
      providing such information.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a randomised, cross-over, open label trial assessing drug interaction between
      paracetamol and nefopam in healthy volunteers.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>July 2014</start_date>
  <completion_date type="Actual">July 2014</completion_date>
  <primary_completion_date type="Actual">July 2014</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Existence of drug interaction</measure>
    <time_frame>AT DAY 1</time_frame>
    <description>Drug metabolites and principle assessing by LC / MS / MS in blood samples. Determining of Cmax, Tmax, AUC and Half-life</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>influence of paracetamol on the kinetics of nefopam</measure>
    <time_frame>AT DAY 1</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Measure of plasma pharmacokinetic parameters of each active metabolites and principles (dosage nefopam, N-desmethyl-nefopam, paracetamol, paracetamol glucuronide, paracetamol sulfate) alone</measure>
    <time_frame>at day 1</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Measure of plasma pharmacokinetic parameters in combination (AUC, Cmax, Tmax, half-life time of apparent elimination terminal).</measure>
    <time_frame>at day 1</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">12</enrollment>
  <condition>Healthy Volunteers</condition>
  <arm_group>
    <arm_group_label>paracetamol</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>drug interaction between paracetamol and nefopam in healthy volunteers.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>paracetamol 1000 mg per os, nefopam 60mg per os, paracetamol 1000 mg + nefopam 60 mg per os</intervention_name>
    <arm_group_label>paracetamol</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age over 18

          -  ALT, AST, PAL, normal GGT, creatinine &lt;133Î¼mol / L, hematocrit&gt;38%

          -  Informed consent to the trial

          -  Healthy volunteers affiliated to the French Social Security
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Claude DUBRAY</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital, Clermont-Ferrand</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>CHU de Clermont-Ferrand</name>
      <address>
        <city>Clermont-Ferrand</city>
        <zip>63003</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>July 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 26, 2014</study_first_submitted>
  <study_first_submitted_qc>June 24, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 25, 2014</study_first_posted>
  <last_update_submitted>July 24, 2014</last_update_submitted>
  <last_update_submitted_qc>July 24, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 25, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Paracetamol</keyword>
  <keyword>Nefopam</keyword>
  <keyword>Pharmacokinetic</keyword>
  <keyword>Drug interaction</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Acetaminophen</mesh_term>
    <mesh_term>Nefopam</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

